

### Clinical trial results:

A Randomized, Open Label, Multicenter Phase IIIb Study Comparing Two Trastuzumab Dosing Regimens, Each in Combination With Cisplatin/Capecitabine Chemotherapy, as First-Line Therapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Adenocarcinoma Who Have Not Received Prior Treatment for Metastatic Disease

Disease	
Summary	
Results information	
Trial information	
Trial identification	
Additional study identifiers	
Sponsors	
Paediatric regulatory details	

Results analysis stage			
General information about the tri	ial		
Population of trial subjects			
Subjects enrolled per country			

Subjects enrolled per age group	

Subject disposition			
Recruitment			
Pre-assignment			
Period 1			
Arms			
Arm title			
	T		
Arm title			

Number of subjects in period 1	

\_

# **Baseline characteristics** Reporting groups Reporting group values

	Τ	Ι	Ι	
End point values				
Lind point values				
Statistical analyses	Τ			
Statistical analysis title				
		· · · · · · · · · · · · · · · · · · ·		
	1			
	1			
		· · · · · · · · · · · · · · · · · · ·		· · · · · · · · · · · · · · · · · · ·
Statistical analysis title				
	_			
	1			

Secondary: Percentage of Partici	nants Who Di	ed - Per Prot	ocal Set (PPS	
- Creentage of Fartier			0001301(110	
	<u> </u>			
End point values				
	l		l	
Statistical analyses				
Secondary: Overall Survival - PPS	5			
	r			

End point values			
	1	l	
Statistical analyses Statistical analysis title	<u> </u>		
Statistical analysis title	<u> </u>		
Statistical analysis title			
	1		

	1			
<b>Secondary: Percentage of Partici</b>	pants With D	isease Progr	ession or Dea	th - PPS
			1	
End point values				
Lind point values				
			+	
			1	
	1	1	1	1
Statistical analyses				
Secondary: Progression-Free Sur	vival - PPS			
	TIVAL - FFS			

End point values			
Life point values			
	ı	<u> </u>	 <u> </u>
Statistical analyses			
Statistical analysis title			
-	Ι		
	l .		
	1		
Statistical analysis title			
<u>-</u>	<u> </u>		
	<u> </u>		
	-		


Secondary: Percentage of Partici	nants With O	hiective Desr	onse - DDS	
	pants tritii O	Jeenve Resp		
End point values				
Statistical analyses				
Statistical analysis title				
	1			
	<u> </u>			


Statistical analysis title	
•	
Secondary: Trastuzumab Cmin o	n Day 21 of Cycles 1 to 11 - FAS
Secondary: Trastuzumab Cmin o	n Day 21 of Cycles 1 to 11 - FAS
Secondary: Trastuzumab Cmin o	n Day 21 of Cycles 1 to 11 - FAS
Secondary: Trastuzumab Cmin o	n Day 21 of Cycles 1 to 11 - FAS
Secondary: Trastuzumab Cmin o	n Day 21 of Cycles 1 to 11 - FAS
Secondary: Trastuzumab Cmin o	n Day 21 of Cycles 1 to 11 - FAS
Secondary: Trastuzumab Cmin o	n Day 21 of Cycles 1 to 11 - FAS
Secondary: Trastuzumab Cmin o	n Day 21 of Cycles 1 to 11 - FAS
Secondary: Trastuzumab Cmin o	n Day 21 of Cycles 1 to 11 - FAS
Secondary: Trastuzumab Cmin o	n Day 21 of Cycles 1 to 11 - FAS
Secondary: Trastuzumab Cmin o	n Day 21 of Cycles 1 to 11 - FAS
Secondary: Trastuzumab Cmin o	n Day 21 of Cycles 1 to 11 - FAS
Secondary: Trastuzumab Cmin o	n Day 21 of Cycles 1 to 11 - FAS
Secondary: Trastuzumab Cmin o	n Day 21 of Cycles 1 to 11 - FAS
Secondary: Trastuzumab Cmin o	n Day 21 of Cycles 1 to 11 - FAS
Secondary: Trastuzumab Cmin o	n Day 21 of Cycles 1 to 11 - FAS
Secondary: Trastuzumab Cmin or	n Day 21 of Cycles 1 to 11 - FAS
Secondary: Trastuzumab Cmin or	n Day 21 of Cycles 1 to 11 - FAS
Secondary: Trastuzumab Cmin or	n Day 21 of Cycles 1 to 11 - FAS
Secondary: Trastuzumab Cmin or	n Day 21 of Cycles 1 to 11 - FAS
Secondary: Trastuzumab Cmin or	n Day 21 of Cycles 1 to 11 - FAS
Secondary: Trastuzumab Cmin o	n Day 21 of Cycles 1 to 11 - FAS
Secondary: Trastuzumab Cmin o	n Day 21 of Cycles 1 to 11 - FAS
Secondary: Trastuzumab Cmin o	n Day 21 of Cycles 1 to 11 - FAS
Secondary: Trastuzumab Cmin o	n Day 21 of Cycles 1 to 11 - FAS


End noint values				
End point values				
Statistical analyses				
Statistical analyses				
Secondary: Trastuzumab Serum	Concentration	n on Day 1 of	Cycle 1 - FAS	3
	T			
	<u> </u>			
End point values				
•				
Statistical analyses				





## **Adverse events Adverse events information Dictionary used Reporting groups** Serious adverse events





















Non-serious adverse events		



## **More information**

## Substantial protocol amendments (globally)

Date	Amendment
Interruption	(globally)
Limitations a	nd caveats